Barry Hammer, PA-C, defines high-risk multiple myeloma and explains the treatment adjustments needed for newly-diagnosed patients.
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.